CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib

2017/05/10 by Triparna Sen, Pan Tong, C. Allison Stewart +16 · 27 citations
Medicine · Biochemistry, Genetics and Molecular Biology · #Lung Cancer Research Studies #Cancer therapeutics and mechanisms #Lung Cancer Treatments and Mutations

paper · doi:10.1158/0008-5472.can-16-3409

Abstract

.

Citations

• Loss of p130 Accelerates Tumor Development in a Mouse Model for Human Small-Cell Lung Carcinoma

Cited by

• Targeting DHX9 Triggers Tumor-Intrinsic Interferon Response and Replication Stress in Small Cell Lung Cancer
• Small cell lung cancer: Subtypes and therapeutic implications
• Protein expression of TTF1 and cMYC define distinct molecular subgroups of small cell lung cancer with unique vulnerabilities to aurora kinase inhibition, DLL3 targeting, and other targeted therapies. [europepmc]
• Development of Chemotherapy with Cell-Cycle Inhibitors for Adult and Pediatric Cancer Therapy. [europepmc]
• Targeting oncogenic Myc as a strategy for cancer treatment. [europepmc]
• Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. [europepmc]
• Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. [europepmc]
• Exploiting DNA repair defects in colorectal cancer. [europepmc]
• Targeting DNA Damage Response Promotes Antitumor Immunity through STING-Mediated T-cell Activation in Small Cell Lung Cancer. [europepmc]
• Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data. [europepmc]
• MYC-Driven Small-Cell Lung Cancer is Metabolically Distinct and Vulnerable to Arginine Depletion. [europepmc]
• Immunotherapy in small-cell lung cancer: from molecular promises to clinical challenges. [europepmc]
• The CHK1 Inhibitor Prexasertib Exhibits Monotherapy Activity in High-Grade Serous Ovarian Cancer Models and Sensitizes to PARP Inhibition. [europepmc]
• Combination Olaparib and Temozolomide in Relapsed Small-Cell Lung Cancer. [europepmc]
• Combination Treatment of the Oral CHK1 Inhibitor, SRA737, and Low-Dose Gemcitabine Enhances the Effect of Programmed Death Ligand 1 Blockade by Modulating the Immune Microenvironment in SCLC. [europepmc]
• Recent progress in mapping the emerging landscape of the small-cell lung cancer genome. [europepmc]
• New Approaches to SCLC Therapy: From the Laboratory to the Clinic. [europepmc]
• MYC Drives Temporal Evolution of Small Cell Lung Cancer Subtypes by Reprogramming Neuroendocrine Fate. [europepmc]
• Targeted Therapies and Biomarkers in Small Cell Lung Cancer. [europepmc]
• Small-cell lung cancer. [europepmc]
• AMBRA1 regulates cyclin D to guard S-phase entry and genomic integrity. [europepmc]
• Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy. [europepmc]
• Molecular Subtypes of Primary SCLC Tumors and Their Associations With Neuroendocrine and Therapeutic Markers. [europepmc]
• WEE1 inhibition enhances the antitumor immune response to PD-L1 blockade by the concomitant activation of STING and STAT1 pathways in SCLC. [europepmc]
• A new wave of innovations within the DNA damage response. [europepmc]
• Emerging advances in defining the molecular and therapeutic landscape of small-cell lung cancer. [europepmc]
• Enhancing transcription-replication conflict targets ecDNA-positive cancers. [europepmc]

Related

• PI3K‐independent AKT activation in cancers: A treasure trove for novel therapeutics
• The PI3K/AKT Pathway as a Target for Cancer Treatment
• Beyond Inhibition: Recent Advances of Heterobifunctional Molecules Targeting CDK9
• CDK9 inhibition by dinaciclib potently suppresses Mcl-1 to induce durable apoptotic responses in aggressive MYC-driven B-cell lymphoma in vivo
• Therapeutic Targets in Non-Small Cell Lung Cancer: Current Progress and Future Directions